Ipsen Lifts 2026 Outlook After First-Half Sales Surge
Ipsen reported first-half revenue of EUR 2.19 billion, a 20.4% increase year-on-year, and raised its full-year 2026 guidance after stronger-than-expected adjusted EBIT and margin improvement. The company cited contributions across its three therapeutic areas and advancements in late-stage programs and acquisitions as drivers of its upgraded outlook…